Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial
/in Dendritic Cells, Endometrial Cancer, International Publications, Ovarian Cancer /von 2002-01-10 / Cancer Immunol. Immunother. 2002 Mar;51(1):45-52Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
/in Dendritic Cells, Endometrial Cancer, International Publications, Ovarian Cancer /von 2002-01-07 / Br. J. Cancer 2002 Jan;86(1):151-7The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2002-01-01 / Int J Gastrointest Cancer 2002;32(1):1-6Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2002-01-01 / Med. Oncol. 2002;19(4):213-8Hyperthermia for rectal cancer
/in Hyperthermia, International Publications /von 2002-01-01 / Surgery 2002 Jan;131(1 Suppl):S121-7
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution